TCS Launches AgentHub to Scale Agentic AI Across Drug Development and Pharmacovigilance
核心洞察
TCS has launched TCS ADD AgentHub (搜索), an enterprise-ready agentic AI platform designed to automate clinical development and drug-safety workflows in highly regulated pharmaceutical environments.
The platform operates on a "human plus AI" model, assigning AI agents defined roles with oversight and built-in auditability while humans retain responsibility for final decisions.
TCS reports efficiency gains of up to 40% in clinical data management, 30% reductions in study setup effort and safety-case processing costs, and up to 50% lower manual effort in drug-safety quality control.
Tata Consultancy Services (搜索) (TCS) has launched TCS ADD AgentHub (搜索), an enterprise-ready, role-based agentic AI platform designed to help pharmaceutical companies scale artificial intelligence across the research and development (R&D) value chain in highly regulated environments. The platform targets clinical trials and pharmacovigilance services, aiming to transform these workflows while maintaining regulatory, governance, and audit requirements.
The launch addresses persistent challenges facing pharmaceutical companies, which operate in highly regulated settings and confront issues related to trust, governance, and scalability when applying AI across functions. TCS noted that growing data volumes, fragmented systems, and increasing regulatory requirements across clinical development and pharmacovigilance are adding complexity to the R&D value chain.
A "Human Plus AI" Operating Model
TCS ADD AgentHub (搜索) provides a structured framework through which AI agents operate with clear roles, defined oversight, and built-in auditability. The platform is designed around a "human plus AI" model, in which agents perform defined tasks while people retain oversight and responsibility for decisions.
"TCS ADD AgentHub (搜索) will enable our customers to accelerate drug development using agentic AI at scale," said Debashis Ghosh, president of lifesciences and healthcare at TCS. "It enables a shift from reactive to proactive, scalable and audit-ready operations amid an ever-changing regulatory environment."
Ghosh added that TCS's strategy is to move toward autonomous enterprise functions where an AI agentic workforce operates alongside humans, driving innovation in drug development and improving patient safety.
Workflow Coverage and Reported Efficiency Gains
The platform supports workflows across clinical development and pharmacovigilance through AI workers that handle tasks such as individual case safety report (ICSR) intake, data entry, medical coding, review, and scientific literature analysis. Within clinical development, its agents can assist with study design, converting clinical protocols into structured digital formats, reviewing clinical data, medical monitoring, and transforming data into the Study Data Tabulation Model (SDTM), a standard used when submitting clinical trial information to regulators.
TCS claims that solutions powered by the platform have demonstrated efficiency improvements of up to 40% in clinical data-management activities. Metadata-led automation can reduce the effort required to set up clinical studies by up to 30%, while automation of end-to-end safety-case processing can generate cost savings of up to 30%. AI agents performing quality-control tasks in drug-safety operations can reduce associated manual effort by as much as 50%.
TCS did not disclose the customers or number of deployments from which these estimates were derived.
Integration and Deployment Approach
Pharmaceutical companies can custom-build their AI agent hub and deploy agents across clinical workflows. The platform allows rapid and streamlined integration with minimal effort, accelerating adoption while maintaining regulatory compliance. It can be integrated with existing pharmaceutical systems and allows companies to introduce agents progressively across different processes rather than attempting an enterprise-wide deployment at once.
AgentHub is built on TCS ADD, the company's suite of software products for clinical research and drug development. The platform contains an expanding catalogue of agents that can be configured according to a pharmaceutical company's processes and technology environment.
By standardizing how AI agents are introduced across workflows, TCS expects the platform to reduce implementation effort and allow scientific and clinical teams to focus on work requiring domain expertise and human judgment. While AgentHub can automate defined steps and provide recommendations, responsibility for governance and final decision-making will continue to rest with human specialists, TCS said.